{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:48:01Z","timestamp":1782848881660,"version":"3.54.5"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    To identify risk factors associated with visual field progression over long-term follow-up (10 years) in patients newly diagnosed with exfoliation glaucoma. This was a non-randomised, prospective cohort study including patients newly diagnosed with exfoliation glaucoma. Visual field progression was assessed using three methods mean deviation (MD), visual field index (VFI), and guided progression analysis (GPA). Baseline variables to be evaluated included intraocular pressure (IOP), sex, age, visual fields, uni- or bilateral presentation, visual acuity, lens status (phakic\/pseudophakic), central corneal thickness (CCT), optic nerve status, and gonioscopy findings. Additionally, a questionnaire on, hypertension, diabetes, migraine, smoking, and family history of glaucoma. Multivariable regression analyses were performed to identify risk factors. A total of 58 patients completed the 10-year follow-up. The IOP at inclusion was 32.06 (\u00b1\u20096.05) mmHg. In the MD model, significant risk factors for progression included older age (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.002), smoking (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.004), phakic lens status (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001), and lower CCT (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.02). In the VFI model, significant risk factors were older age (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.009) and smoking (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.04). In the GPA model, risk factors included older age (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.001) and smoking (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.01). Older age at diagnosis and a history of smoking were found to be significantly associated with an increased risk of long-term visual field progression.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-60254-x","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:58:00Z","timestamp":1782788280000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk factors for visual field progression during 10-year follow-up in newly diagnosed exfoliation glaucoma patients"],"prefix":"10.1038","volume":"16","author":[{"given":"Marcelo","family":"Ayala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Dahlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"Suppl 1","key":"60254_CR1","first-page":"1","volume":"105","author":"European Glaucoma Society","year":"2021","unstructured":"European Glaucoma Society Terminology and Guidelines for Glaucoma, 5th Edition. Br. J. Ophthalmol. 105 (Suppl 1), 1\u2013169 (2021).","journal-title":"Br. J. Ophthalmol."},{"issue":"1","key":"60254_CR2","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1186\/s12886-020-01592-w","volume":"20","author":"M Ayala","year":"2020","unstructured":"Ayala, M. Comparison of visual field progression in new-diagnosed primary open-angle and exfoliation glaucoma patients in Sweden. BMC Ophthalmol. 20 (1), 322 (2020).","journal-title":"BMC Ophthalmol."},{"issue":"2","key":"60254_CR3","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1097\/ICU.0000000000000736","volume":"32","author":"U Schlotzer-Schrehardt","year":"2021","unstructured":"Schlotzer-Schrehardt, U. & Khor, C. C. Pseudoexfoliation syndrome and glaucoma: From genes to disease mechanisms. Curr. Opin. Ophthalmol. 32 (2), 118\u2013128 (2021).","journal-title":"Curr. Opin. Ophthalmol."},{"issue":"6","key":"60254_CR4","doi-asserted-by":"publisher","first-page":"e505","DOI":"10.1111\/aos.12918","volume":"94","author":"LR Pasquale","year":"2016","unstructured":"Pasquale, L. R., Borras, T., Fingert, J. H., Wiggs, J. L. & Ritch, R. Exfoliation syndrome: Assembling the puzzle pieces. Acta Ophthalmol. 94 (6), e505\u2013e512 (2016).","journal-title":"Acta Ophthalmol."},{"issue":"9","key":"60254_CR5","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.3390\/genes12091384","volume":"12","author":"M Ayala","year":"2021","unstructured":"Ayala, M., Zetterberg, M., Skoog, I. & Zettergren, A. Association of single nucleotide polymorphisms located in LOXL1 with exfoliation glaucoma in Southwestern Sweden. Genes (Basel). 12 (9), 1384. https:\/\/doi.org\/10.3390\/genes12091384 (2021).","journal-title":"Genes (Basel)"},{"key":"60254_CR6","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.ajo.2017.06.003","volume":"180","author":"TCW Chan","year":"2017","unstructured":"Chan, T. C. W., Bala, C., Siu, A., Wan, F. & White, A. Risk factors for rapid glaucoma disease progression. Am. J. Ophthalmol. 180, 151\u2013157 (2017).","journal-title":"Am. J. Ophthalmol."},{"key":"60254_CR7","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ajo.2019.06.019","volume":"207","author":"JH Kim","year":"2019","unstructured":"Kim, J. H. et al. Risk factors for fast visual field progression in glaucoma. Am. J. Ophthalmol. 207, 268\u2013278 (2019).","journal-title":"Am. J. Ophthalmol."},{"issue":"3","key":"60254_CR8","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.ophtha.2012.09.005","volume":"120","author":"PJ Ernest","year":"2013","unstructured":"Ernest, P. J. et al. An evidence-based review of prognostic factors for glaucomatous visual field progression. Ophthalmology 120 (3), 512\u2013519 (2013).","journal-title":"Ophthalmology"},{"issue":"2","key":"60254_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1111\/aos.16600","volume":"102","author":"A Heijl","year":"2024","unstructured":"Heijl, A. New Finnish and Swedish glaucoma guidelines. Acta Ophthalmol. 102 (2), 133\u2013134 (2024).","journal-title":"Acta Ophthalmol."},{"issue":"6","key":"60254_CR10","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass, M. A. et al. The ocular hypertension treatment study: A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch. Ophthalmol. 120 (6), 701 (2002).","journal-title":"Arch. Ophthalmol."},{"issue":"9","key":"60254_CR11","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.ophtha.2005.05.024","volume":"112","author":"HA Quigley","year":"2005","unstructured":"Quigley, H. A. European glaucoma prevention study. Ophthalmology 112 (9), 1642\u20131643 (2005). author reply 3\u20135.","journal-title":"Ophthalmology"},{"issue":"9","key":"60254_CR12","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1016\/j.ophtha.2011.01.047","volume":"118","author":"DC Musch","year":"2011","unstructured":"Musch, D. C., Gillespie, B. W., Niziol, L. M., Lichter, P. R. & Varma, R. Intraocular pressure control and long-term visual field loss in the Collaborative Initial Glaucoma Treatment Study. Ophthalmology 118 (9), 1766\u20131773 (2011).","journal-title":"Ophthalmology"},{"key":"60254_CR13","unstructured":"Hodapp, E., Parrish, R. K. & Anderson, D. R. Clinical Decisions in Glaucoma (Mosby, 1993)."},{"issue":"1","key":"60254_CR14","doi-asserted-by":"publisher","first-page":"e000262","DOI":"10.1136\/fmch-2019-000262","volume":"8","author":"MZI Chowdhury","year":"2020","unstructured":"Chowdhury, M. Z. I. & Turin, T. C. Variable selection strategies and its importance in clinical prediction modelling. Fam Med. Community Health. 8 (1), e000262 (2020).","journal-title":"Fam Med. Community Health"},{"key":"60254_CR15","doi-asserted-by":"crossref","unstructured":"Ayala, M. Risk factors and frequency of examinations for detecting visual field deterioration in patients newly diagnosed exfoliation glaucoma in Sweden. J. Glaucoma 33, 168\u2013175 (2023).","DOI":"10.1097\/IJG.0000000000002319"},{"issue":"1","key":"60254_CR16","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/archopht.121.1.48","volume":"121","author":"MC Leske","year":"2003","unstructured":"Leske, M. C. et al. Factors for glaucoma progression and the effect of treatment: The early manifest glaucoma trial. Arch. Ophthalmol. 121 (1), 48\u201356 (2003).","journal-title":"Arch. Ophthalmol."},{"key":"60254_CR17","doi-asserted-by":"publisher","first-page":"563","DOI":"10.2147\/OPTH.S498422","volume":"19","author":"D Agbato","year":"2025","unstructured":"Agbato, D., Rickford, K. & Laroche, D. Central corneal thickness and glaucoma risk: The importance of corneal pachymetry in screening adults over 50 and glaucoma suspects. Clin. Ophthalmol. 19, 563\u2013570 (2025).","journal-title":"Clin. Ophthalmol."},{"key":"60254_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ajo.2021.07.008","volume":"236","author":"SL Mansberger","year":"2022","unstructured":"Mansberger, S. L., Gardiner, S. K., Gordon, M., Kass, M. & Ramulu, P. Cataract surgery lowers intraocular pressure and medication use in the medication group of the ocular hypertension treatment study. Am. J. Ophthalmol. 236, 53\u201362 (2022).","journal-title":"Am. J. Ophthalmol."},{"issue":"12","key":"60254_CR19","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1016\/j.ophtha.2020.06.009","volume":"127","author":"P Founti","year":"2020","unstructured":"Founti, P. et al. Risk factors for visual field deterioration in the UK glaucoma treatment study. Ophthalmology 127 (12), 1642\u20131651 (2020).","journal-title":"Ophthalmology"},{"key":"60254_CR20","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ajo.2019.08.023","volume":"209","author":"JC Han","year":"2020","unstructured":"Han, J. C., Han, S. H., Park, D. Y., Lee, E. J. & Kee, C. Clinical course and risk factors for visual field progression in normal-tension glaucoma with myopia without glaucoma medications. Am. J. Ophthalmol. 209, 77\u201387 (2020).","journal-title":"Am. J. Ophthalmol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60254-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60254-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60254-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T18:57:52Z","timestamp":1782845872000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-60254-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["60254"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-60254-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"13 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}],"article-number":"19909"}}